Alar Pharmaceuticals Inc. (6785.TWO)
TWD 138.5
(-1.07%)
TWD 138.5
(-1.07%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | 403.57 Million | -32.94 Million | -63.47 Million | -141.92 Million | - |
| Net Income | 391.1 Million | -32.53 Million | -64.23 Million | -142.79 Million | - |
| Depreciation & Amortization | 3.35 Million | 3.2 Million | 3.35 Million | 2.84 Million | - |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | - | - | 360 Thousand | - |
| Change in working capital | 27.25 Million | -788 Thousand | -1.1 Million | -705 Thousand | - |
| Other non-cash items | -16.85 Million | -2.76 Million | -1.47 Million | -1.59 Million | - |
| Investing Cash Flow | -118.17 Million | -29.83 Million | 22.51 Million | 104.31 Million | - |
| Investments in PPE | -6.33 Million | -1.13 Million | -1.57 Million | -385 Thousand | - |
| Acquisitions | - | - | - | - | - |
| Investment purchases | -125.66 Million | -30.86 Million | - | - | - |
| Sales/Maturities of investments | - | - | 22.67 Million | 105.84 Million | 5.91 Million |
| Other Investing Activities | -200 Thousand | -212 Thousand | -80 Thousand | -2.77 Million | - |
| Financing Cash Flow | -1.28 Million | -929 Thousand | -932 Thousand | 549.1 Million | - |
| Debt repayment | -1.28 Million | - | - | - | - |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | - | - | - | 550 Million | - |
| Other Financing Activities | -1.28 Million | - | - | - | - |
| Accounts receivables | 840 Thousand | - | - | - | - |
| Accounts payables | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other working capital | 26.41 Million | - | - | - | - |
| Cash at beginning of period | 455.35 Million | 519.06 Million | 560.95 Million | 49.45 Million | - |
| Cash at end of period | 739.46 Million | 455.35 Million | 519.06 Million | 560.95 Million | - |
| Capital Expenditure | -6.33 Million | -1.13 Million | -1.57 Million | -385 Thousand | - |
| Effect of forex changes on cash | - | - | - | - | - |
| Net cash flow / Change in cash | 284.11 Million | -63.71 Million | -41.89 Million | 511.5 Million | - |
| Free Cash Flow | 397.23 Million | -34.08 Million | -65.04 Million | -142.3 Million | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 8.15 Million | 17.76 Million | 415.92 Million | 391.1 Million | 1.05 Million | -8.68 Million |
| Depreciation & Amortization | 948 Thousand | 914 Thousand | 901 Thousand | 3.35 Million | 891 Thousand | 822 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | 848 Thousand | - | - | - | - |
| Change in working capital | -17.09 Million | 2.75 Million | -134.05 Million | 27.25 Million | -3.03 Million | 14.67 Million |
| Other non-cash items | -16.06 Million | -11.24 Million | -6.55 Million | -16.85 Million | -4.19 Million | -4.03 Million |
| Investing Cash Flow | 126.86 Million | -1.74 Billion | -149.85 Million | -118.17 Million | 138 Thousand | 31.05 Million |
| Investments in PPE | -732 Thousand | -1 Million | - | -6.33 Million | -1.1 Million | -5.23 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | 145.74 Million | -1.75 Billion | -125.66 Million | -125.66 Million | - | - |
| Sales/Maturities of investments | - | - | - | - | -2.9 Million | 30.59 Million |
| Other Investing Activities | 127.59 Million | 1.8 Million | -430 Thousand | -200 Thousand | - | 1.57 Million |
| Financing Cash Flow | -100.53 Million | 1.67 Billion | -325 Thousand | -1.28 Million | -322 Thousand | -320 Thousand |
| Debt repayment | -335 Thousand | - | - | - | - | - |
| Dividends payments | -100.2 Million | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 1.67 Billion | - | - | - | - |
| Other Financing Activities | -335 Thousand | - | - | - | - | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | -273 Thousand | - | - | - | - | - |
| Cash at beginning of period | 677.72 Million | 739.46 Million | 613.86 Million | 455.35 Million | 619.62 Million | 586.64 Million |
| Cash at end of period | 677.44 Million | 677.72 Million | 739.46 Million | 739.46 Million | 613.86 Million | 619.62 Million |
| Capital Expenditure | -732 Thousand | -1 Million | - | -6.33 Million | -1.1 Million | -5.23 Million |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -277 Thousand | -61.74 Million | 125.6 Million | 284.11 Million | -5.76 Million | 32.98 Million |
| Free Cash Flow | -27.33 Million | 8.98 Million | 275.77 Million | 397.23 Million | -6.68 Million | -2.98 Million |
1802
YOU
ACGL
CLVSF
3631
RIOT